Rebecca Taub

CEO at Madrigal Pharmaceuticals - Conshohocken, PA, US

Rebecca Taub's Colleagues at Madrigal Pharmaceuticals
Ed Chiang

Vice President, Clinical Operations

Contact Ed Chiang

Daniel Whittaker

Vice President, Commercial Planning

Contact Daniel Whittaker

Ivan Qutier

Field Medical Advisor

Contact Ivan Qutier

Barton Isaac

Field Director East, Medical Affairs

Contact Barton Isaac

David Schneider

Vice President Clinical Development

Contact David Schneider

Robert Waltermire

Chief Pharmaceutical Development Officer

Contact Robert Waltermire

Mark Ferguson

Senior Director of Project Management

Contact Mark Ferguson

View All Rebecca Taub's Colleagues
Rebecca Taub's Contact Details
HQ
484-380-9263
Location
Villanova, Pennsylvania
Company
Madrigal Pharmaceuticals
Rebecca Taub's Company Details
Madrigal Pharmaceuticals logo, Madrigal Pharmaceuticals contact details

Madrigal Pharmaceuticals

Conshohocken, PA, US • 50 - 99 Employees
Major Drugs

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company has advanced its lead candidate, resmetirom, also known as MGL-3196, a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist, through Phase 2 clinical trials in NASH. Primary and key secondary endpoints were achieved including reduction of liver fat on a sensitive non-invasive imaging test, lowering of multiple atherogenic lipids including LDL-cholesterol and triglycerides, and resolution of NASH on liver biopsy.Based on evidence of broad activity and a favorable safety profile, Madrigal has initiated a Phase 3 clinical study in NASH patients with advanced liver fibrosis, MAESTRO-NASH, in which the primary endpoint after one year of dosing is resolution of NASH and key secondary endpoints include LDL-cholesterol lowering and reduction in liver fibrosis. Clinical benefit in reducing progression to more advanced liver disease, including cirrhosis, is a long-term goal of this trial.A second Phase 3 clinical study, MAESTRO-NAFLD-1, has also been initiated. This 52-week non-invasive study in a broader segment of NASH patients will provide additional safety information to support the NASH indication and will include key efficacy endpoints: LDL-cholesterol lowering, triglyceride lowering, reduction of liver fat as determined by MRI-PDFF, as well as reduction of elevated liver enzymes and reduction in fibrosis biomarkers. This is a non-biopsy study in people with NASH, as documented using non-invasive techniques or historical liver biopsy.For more information about Madrigal, please visit out website at https://www.madrigalpharma.com/ and follow us on Twitter at @MadrigalPharma.

Biotechnology Cleantech Healthcare Pharmaceuticals Wind Power Major Drugs Pharmaceutical Preparations
Details about Madrigal Pharmaceuticals
Frequently Asked Questions about Rebecca Taub
Rebecca Taub currently works for Madrigal Pharmaceuticals.
Rebecca Taub's role at Madrigal Pharmaceuticals is CEO.
Rebecca Taub's email address is ***@madrigalpharma.com. To view Rebecca Taub's full email address, please signup to ConnectPlex.
Rebecca Taub works in the Major Drugs industry.
Rebecca Taub's colleagues at Madrigal Pharmaceuticals are Ed Chiang, Daniel Whittaker, Ivan Qutier, Barton Isaac, David Schneider, Robert Waltermire, Mark Ferguson and others.
Rebecca Taub's phone number is 484-380-9263
See more information about Rebecca Taub